The S&P BSE Sensex ended 190 points up at 23,382.
The case was earlier heard by a different vacation bench which had on June 10 asked Sharma to substantiate his 'unfounded allegations' that the Indian pharma major was allegedly manufacturing and selling adulterated medicines.
Ohm Laboratories Inc, a wholly-owned subsidiary of Ranbaxy has received approval from the US Food and Drug Administration for manufacturing and marketing Valsartan tablets in strengths of 40 mg, 80 mg, 160 mg, and 320 mg on an exclusive basis, Ranbaxy Laboratories said in a statement.
Lupin was the top gainer after the USFDA cleared its Goa facility
Experts suggest six ways to play stocks that tank suddenly and make money as Sanjay Kumar Singh listens in
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
The BSE Midcap also cut all its intraday gains to shed 0.3% at close
Viveka Kumar lists the factors you need to keep in mind.
The market breadth, indicating the overall health of the market, was positive
Nifty PSU bank index dropped nearly 2%
Exports from Ranbaxy plants at Toansa and Dewas to Europe will remain suspended as probes are continuing even as Indian authorities have withdrawn the certification of manufacturing standards from one of the units, European health regulator EMA said today.
The broader NSE Nifty too dived by 101.65 points, or 0.97 per cent, to close at 10,350.15.
Ranbaxy Laboratories on Thursday said it will co-operate fully with any regulator from anywhere in the world wanting to investigate its manufacturing practices.
In the longest losing streak of 2017, the BSE Sensex has lost 1,270 points, or 3.91 per cent. It fell to a three-month low of 31,154.03 on Wednesday.
Investors have kept their eyes on US-China trade talks and are optimistic about a positive outcome.
Ranbaxy, which is 63.5 per cent-owned by Japan's Daiichi Sankyo Co and gets more than 40 per cent of its sales from the United States, did not immediately respond to a request on Wednesday for comment on the FDA observations.
Broader market outperformed the benchmark indices with S&P BSE Midcap gaining over 1%
Top 5 losers include Lupin, Cipla, Sun Pharma, Dr Reddy's Lab and GAIL down 1.6%-11%.
'India is too large a place to have just 10 labs performing these Covid-19 tests.'
ITC, Sun Pharma, Cipla and Tata Steel were top gainers on BSE Sensex
HSBC maintained "overweight" rating on Indian equities, saying "fundamentals are strong".
Maruti Suzuki, Asian Paints, L&T, ONGC and Infosys have gained between 1%-1.5%.
.jpg)
The company has been reported to be retrenching staff.
'... And I don't think it really is that despite a lot going wrong.' 'Naiveté or stupidity or trusting the wrong person, the outcome is the same, which is that the group has gone to trash.' 'I'm not OK with people saying I had a role to play in crooking the system, which is not what I did.'
Private lenders HDFC Bank and ICICI Bank were the top gainers along with index heavyweights
The winter session of Parliament will commence on November 26.
Ranbaxy Laboratories on Wednesday reported widening of its consolidated net loss to Rs 1,029.72 crore (Rs 10.29 billion) for the third quarter ended December 31, 2014
TCS, Infosys and Wipro were down 0.4-2% each. Capital goods majors also ended lower with L&T and BHEL down 1.4-3.9% each.
Among other stocks, IT firm Mphasis today reported a 15.30% increase in consolidated net profit at Rs 184.72 crore for the quarter ended September 30, 2015.
Investors indulged in profit booking at attractive and higher valuations
Hit by the new drug pricing policy and regulatory interventions, growth rate of the Rs 72,069-crore Indian pharmaceutical market has slowed down to 9.8 per cent in 2013 as compared to 16.6 per cent in 2012, says a report.
Nifty crosses 9,750-mark; Bharti Airtel, TCS, Wipro, Lupin and Coal India gained the most on BSE Sensex
Financials emerged as the top gainers while auto shares rallied on robust September sales
Broader markets outperformed with BSE Midcap and BSE Smallcap adding 0.23% and 0.45%, respectively
Nifty50 surged 145 points to close at 8,468 after hitting an intra-day high of 8,475.
But splitting management bandwidth by investing in non-core businesses will not be appreciated by the market in the long run.
Gains were led by Tata Motors amid robust sales in June along with select financials.
Markets finished lower for the sixth consecutive day as hopes of the Goods and Services tax (GST) bill being passed in the current session of the Parliament faded considerably.
Participants will watch out for the Brexit poll outcome in the late morning trades tomorrow.
Sensex,Nifty to remain under pressure through the week.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances